{"url": "https://chelate.wordpress.com/report/", "query": "oral chelation heart disease", "actual-search-type": "t", "contents": "<!DOCTYPE html>\n<html lang=\"en\">\n<head>\n<meta charset=\"UTF-8\" />\n<title>Report | EDTA Chelation: A Factual Blog</title>\n<link rel=\"profile\" href=\"http://gmpg.org/xfn/11\" />\n<link rel=\"pingback\" href=\"https://chelate.wordpress.com/xmlrpc.php\" />\n<link rel='dns-prefetch' href='//s2.wp.com' />\n<link rel='dns-prefetch' href='//s0.wp.com' />\n<link rel='dns-prefetch' href='//s1.wp.com' />\n<link rel=\"alternate\" type=\"application/rss+xml\" title=\"EDTA Chelation: A Factual Blog &raquo; Feed\" href=\"https://chelate.wordpress.com/feed/\" />\n<link rel=\"alternate\" type=\"application/rss+xml\" title=\"EDTA Chelation: A Factual Blog &raquo; Comments Feed\" href=\"https://chelate.wordpress.com/comments/feed/\" />\n<link rel=\"alternate\" type=\"application/rss+xml\" title=\"EDTA Chelation: A Factual Blog &raquo; Report Comments Feed\" href=\"https://chelate.wordpress.com/report/feed/\" />\n\t<script type=\"text/javascript\">\n\t\t/* <![CDATA[ */\n\t\tfunction addLoadEvent(func) {\n\t\t\tvar oldonload = window.onload;\n\t\t\tif (typeof window.onload != 'function') {\n\t\t\t\twindow.onload = func;\n\t\t\t} else {\n\t\t\t\twindow.onload = function () {\n\t\t\t\t\toldonload();\n\t\t\t\t\tfunc();\n\t\t\t\t}\n\t\t\t}\n\t\t}\n\t\t/* ]]> */\n\t</script>\n\t\t\t<script type=\"text/javascript\">\n\t\t\twindow._wpemojiSettings = {\"baseUrl\":\"https:\\/\\/s0.wp.com\\/wp-content\\/mu-plugins\\/wpcom-smileys\\/twemoji\\/2\\/72x72\\/\",\"ext\":\".png\",\"svgUrl\":\"https:\\/\\/s0.wp.com\\/wp-content\\/mu-plugins\\/wpcom-smileys\\/twemoji\\/2\\/svg\\/\",\"svgExt\":\".svg\",\"source\":{\"concatemoji\":\"https:\\/\\/s1.wp.com\\/wp-includes\\/js\\/wp-emoji-release.min.js?m=1473172720h&ver=4.6.1-RC1-38499\"}};\n\t\t\t!function(a,b,c){function d(a){var c,d,e,f,g,h=b.createElement(\"canvas\"),i=h.getContext&&h.getContext(\"2d\"),j=String.fromCharCode;if(!i||!i.fillText)return!1;switch(i.textBaseline=\"top\",i.font=\"600 32px Arial\",a){case\"flag\":return i.fillText(j(55356,56806,55356,56826),0,0),!(h.toDataURL().length<3e3)&&(i.clearRect(0,0,h.width,h.height),i.fillText(j(55356,57331,65039,8205,55356,57096),0,0),c=h.toDataURL(),i.clearRect(0,0,h.width,h.height),i.fillText(j(55356,57331,55356,57096),0,0),d=h.toDataURL(),c!==d);case\"diversity\":return i.fillText(j(55356,57221),0,0),e=i.getImageData(16,16,1,1).data,f=e[0]+\",\"+e[1]+\",\"+e[2]+\",\"+e[3],i.fillText(j(55356,57221,55356,57343),0,0),e=i.getImageData(16,16,1,1).data,g=e[0]+\",\"+e[1]+\",\"+e[2]+\",\"+e[3],f!==g;case\"simple\":return i.fillText(j(55357,56835),0,0),0!==i.getImageData(16,16,1,1).data[0];case\"unicode8\":return i.fillText(j(55356,57135),0,0),0!==i.getImageData(16,16,1,1).data[0];case\"unicode9\":return i.fillText(j(55358,56631),0,0),0!==i.getImageData(16,16,1,1).data[0]}return!1}function e(a){var c=b.createElement(\"script\");c.src=a,c.type=\"text/javascript\",b.getElementsByTagName(\"head\")[0].appendChild(c)}var f,g,h,i;for(i=Array(\"simple\",\"flag\",\"unicode8\",\"diversity\",\"unicode9\"),c.supports={everything:!0,everythingExceptFlag:!0},h=0;h<i.length;h++)c.supports[i[h]]=d(i[h]),c.supports.everything=c.supports.everything&&c.supports[i[h]],\"flag\"!==i[h]&&(c.supports.everythingExceptFlag=c.supports.everythingExceptFlag&&c.supports[i[h]]);c.supports.everythingExceptFlag=c.supports.everythingExceptFlag&&!c.supports.flag,c.DOMReady=!1,c.readyCallback=function(){c.DOMReady=!0},c.supports.everything||(g=function(){c.readyCallback()},b.addEventListener?(b.addEventListener(\"DOMContentLoaded\",g,!1),a.addEventListener(\"load\",g,!1)):(a.attachEvent(\"onload\",g),b.attachEvent(\"onreadystatechange\",function(){\"complete\"===b.readyState&&c.readyCallback()})),f=c.source||{},f.concatemoji?e(f.concatemoji):f.wpemoji&&f.twemoji&&(e(f.twemoji),e(f.wpemoji)))}(window,document,window._wpemojiSettings);\n\t\t</script>\n\t\t<style type=\"text/css\">\nimg.wp-smiley,\nimg.emoji {\n\tdisplay: inline !important;\n\tborder: none !important;\n\tbox-shadow: none !important;\n\theight: 1em !important;\n\twidth: 1em !important;\n\tmargin: 0 .07em !important;\n\tvertical-align: -0.1em !important;\n\tbackground: none !important;\n\tpadding: 0 !important;\n}\n</style>\n<link rel='stylesheet' id='all-css-0-1' href='https://s1.wp.com/_static/??-eJx9j1uuwjAMRDdEsJB6eXygu5Y0mGKIE6t2hbp7UioQL+UnmknmOGO4igs5GSYDHpzEoaOkcJWQ2SlTxPHDLYPqAn5jkS6ocEYTHy7u7mpxSkdKZCPYCbmAMrRwj7FYjQu5x3LP4m1KMB7IYywjUhVjWT+oSZ5Kx2q9ee22lR5VXTmZBnZz1y/uxwqgNkackwQpG5UXfYra1x1mF3PwRjm9GXeMnvoa2mMbc1dkByX1Yifon/er5m/XNNvNqjnfAKbVv2Y=' type='text/css' media='all' />\n<link rel='stylesheet' id='print-css-1-1' href='https://s0.wp.com/wp-content/mu-plugins/global-print/global-print.css?m=1465851035h' type='text/css' media='print' />\n<link rel='stylesheet' id='all-css-2-1' href='https://s1.wp.com/_static/??/wp-content/mu-plugins/actionbar/actionbar.css,/wp-content/themes/h4/global.css?m=1476338670j' type='text/css' media='all' />\n<script type='text/javascript' src='https://s0.wp.com/_static/??-eJyFzt0KwjAMBeAXsiv+Tb0Qn6WrcaQuaW1Shz69HeiFMBQCgZyPQ+yYDLIfyhnEhjq3AvnxXk2Qhf0FDGGfnUJDyB/sIyuwTpZihwOYIpBdX2+16BJnXIqiBCIVzaTfLyHfEca/LIAm568mg+Bzaj3Rcblp2+1qfdjtwws0V1vd'></script>\n<link rel='stylesheet' id='all-css-0-2' href='https://s1.wp.com/wp-content/mu-plugins/highlander-comments/style.css?m=1377793621h' type='text/css' media='all' />\n<!--[if lt IE 8]>\n<link rel='stylesheet' id='highlander-comments-ie7-css'  href='https://s1.wp.com/wp-content/mu-plugins/highlander-comments/style-ie7.css?m=1351637563h&#038;ver=20110606' type='text/css' media='all' />\n<![endif]-->\n<link rel=\"EditURI\" type=\"application/rsd+xml\" title=\"RSD\" href=\"https://chelate.wordpress.com/xmlrpc.php?rsd\" />\n<link rel=\"wlwmanifest\" type=\"application/wlwmanifest+xml\" href=\"https://s1.wp.com/wp-includes/wlwmanifest.xml\" /> \n<meta name=\"generator\" content=\"WordPress.com\" />\n<link rel=\"canonical\" href=\"https://chelate.wordpress.com/report/\" />\n<link rel='shortlink' href='http://wp.me/P5dBC-a' />\n<link rel=\"alternate\" type=\"application/json+oembed\" href=\"https://public-api.wordpress.com/oembed/1.0/?format=json&amp;url=https%3A%2F%2Fchelate.wordpress.com%2Freport%2F&amp;for=wpcom-auto-discovery\" /><link rel=\"alternate\" type=\"application/xml+oembed\" href=\"https://public-api.wordpress.com/oembed/1.0/?format=xml&amp;url=https%3A%2F%2Fchelate.wordpress.com%2Freport%2F&amp;for=wpcom-auto-discovery\" />\n<!-- Jetpack Open Graph Tags -->\n<meta property=\"og:type\" content=\"article\" />\n<meta property=\"og:title\" content=\"Report\" />\n<meta property=\"og:url\" content=\"https://chelate.wordpress.com/report/\" />\n<meta property=\"og:description\" content=\"EDTA Chelation: An Alternative Therapy This report summarizes the history of chelation therapy using ethylenediaminetetraacetic acid (EDTA) as a treatment to improve cardiovascular and overall func\u2026\" />\n<meta property=\"article:published_time\" content=\"2007-06-16T00:10:41+00:00\" />\n<meta property=\"article:modified_time\" content=\"2007-06-16T00:10:41+00:00\" />\n<meta property=\"og:site_name\" content=\"EDTA Chelation: A Factual Blog\" />\n<meta property=\"og:image\" content=\"https://s0.wp.com/i/blank.jpg\" />\n<meta property=\"og:locale\" content=\"en_US\" />\n<meta name=\"twitter:site\" content=\"@wordpressdotcom\" />\n<meta name=\"twitter:card\" content=\"summary\" />\n<meta property=\"fb:app_id\" content=\"249643311490\" />\n<meta property=\"article:publisher\" content=\"https://www.facebook.com/WordPresscom\" />\n<link rel=\"shortcut icon\" type=\"image/x-icon\" href=\"https://s2.wp.com/i/favicon.ico\" sizes=\"16x16 24x24 32x32 48x48\" />\n<link rel=\"icon\" type=\"image/x-icon\" href=\"https://s2.wp.com/i/favicon.ico\" sizes=\"16x16 24x24 32x32 48x48\" />\n<link rel=\"apple-touch-icon-precomposed\" href=\"https://s0.wp.com/i/webclip.png\" />\n<link rel='openid.server' href='https://chelate.wordpress.com/?openidserver=1' />\n<link rel='openid.delegate' href='https://chelate.wordpress.com/' />\n<link rel=\"search\" type=\"application/opensearchdescription+xml\" href=\"https://chelate.wordpress.com/osd.xml\" title=\"EDTA Chelation: A Factual Blog\" />\n<link rel=\"search\" type=\"application/opensearchdescription+xml\" href=\"https://s1.wp.com/opensearch.xml\" title=\"WordPress.com\" />\n<meta name=\"application-name\" content=\"EDTA Chelation: A Factual Blog\" /><meta name=\"msapplication-window\" content=\"width=device-width;height=device-height\" /><meta name=\"msapplication-task\" content=\"name=Subscribe;action-uri=https://chelate.wordpress.com/feed/;icon-uri=https://s2.wp.com/i/favicon.ico\" /><meta name=\"msapplication-task\" content=\"name=Sign up for a free blog;action-uri=http://wordpress.com/signup/;icon-uri=https://s2.wp.com/i/favicon.ico\" /><meta name=\"msapplication-task\" content=\"name=WordPress.com Support;action-uri=http://support.wordpress.com/;icon-uri=https://s2.wp.com/i/favicon.ico\" /><meta name=\"msapplication-task\" content=\"name=WordPress.com Forums;action-uri=http://forums.wordpress.com/;icon-uri=https://s2.wp.com/i/favicon.ico\" /><meta name=\"title\" content=\"Report | EDTA Chelation: A Factual Blog on WordPress.com\" />\n<meta name=\"description\" content=\"EDTA Chelation: An Alternative Therapy This report summarizes the history of chelation therapy using ethylenediaminetetraacetic acid (EDTA) as a treatment to improve cardiovascular and overall function.\u00a0 Randomized, double blind, placebo controlled studies and other sources are considered in speculating on the benefits and risks of intravenous and oral forms of this therapy. \u00a0 Mainstream Uses&hellip;\" />\n<style type=\"text/css\">\n#headerimg{\n\tbackground: url(https://s0.wp.com/wp-content/themes/pub/contempt/images/blue_flower/head.jpg) no-repeat;\n}\n#header h1 a, .description {\n\tcolor:#E5F2E9;\n}\n</style>\n<style type=\"text/css\" id=\"syntaxhighlighteranchor\"></style>\n</head>\n<body class=\"page page-id-10 page-template-default mp6 customizer-styles-applied highlander-enabled highlander-light\">\n\n<div id=\"page\">\n\n<div id=\"header\">\n\t<div id=\"headerimg\" onclick=\"location.href='https://chelate.wordpress.com';\" style=\"cursor: pointer;\">\n\t\t<h1><a href=\"https://chelate.wordpress.com/\">EDTA Chelation: A Factual Blog</a></h1>\n\t\t<div class=\"description\"></div>\n\t</div>\n</div>\n\n<ul id=\"pagebar\" class=\"menu pagebar\"><li ><a href=\"https://chelate.wordpress.com/\">Home</a></li><li class=\"page_item page-item-9\"><a href=\"https://chelate.wordpress.com/about/\">About</a></li><li class=\"page_item page-item-6\"><a href=\"https://chelate.wordpress.com/references/\">References</a></li><li class=\"page_item page-item-10 current_page_item\"><a href=\"https://chelate.wordpress.com/report/\">Report</a></li></ul>\n\n<div id=\"grad\" style=\"height: 65px; width: 100%; background: url(https://s0.wp.com/wp-content/themes/pub/contempt/images/blue_flower/topgrad.jpg);\">&nbsp;</div>\n\n\t<div id=\"content\" class=\"narrowcolumn\">\n\n    \t\t<div class=\"post post-10 page type-page status-publish hentry\" id=\"post-10\">\n\t\t<h2>Report</h2>\n\t\t\t<div class=\"entry\">\n\t\t\t\t<p class=\"MsoNormal\"><strong><span style=\"font-size:16pt;\">EDTA Chelation: An Alternative Therapy</span></strong></p>\n<p class=\"MsoNormal\">This report summarizes the history of chelation therapy using ethylenediaminetetraacetic acid (EDTA) as a treatment to improve cardiovascular and overall function.<span>\u00a0 </span>Randomized, double blind, placebo controlled studies and other sources are considered in speculating on the benefits and risks of intravenous and oral forms of this therapy.</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\"><em>Mainstream Uses for Chelation</em></p>\n<p class=\"MsoNormal\">The use of the chelating agent EDTA as a therapeutic stems from its success as a treatment for lead and other heavy metal poisoning.<span>\u00a0 </span>Today, dimercaprol is the often the chelation agent of choice in this scenario, with intravenous or oral EDTA indicated as an add-on therapy (Habal et al., 2006).<span>\u00a0 </span>EDTA is exclusively excreted in the urine.<span>\u00a0 </span>It has a plasma half-life of 1.4 to 3 hours.<span>\u00a0 </span>The FDA-approved purpose for EDTA is to treat lead poisoning and as a diagnostic for total lead burden in the body (Klasco, 2007).</p>\n<p class=\"MsoNormal\"><em>\u00a0</em></p>\n<p class=\"MsoNormal\"><em>Alternative Uses for Chelation</em></p>\n<p class=\"MsoNormal\">The idea that chelation therapy with EDTA could elicit cardiovascular benefit emerged more than 50 years ago.<span>\u00a0 </span>Physicians reported cases in which EDTA intravenous therapy improved coronary artery disease symptoms (Clarke et al., 1955) and signs of atherosclerosis (Clarke et al., 1956), and speculated that EDTA-related calcium sequestration leads to reduction of atherosclerotic plaques (Clarke et al., 1956).<span>\u00a0 </span>A plethora of case studies emerged since that time describing the use of EDTA to improve cardiovascular function (Seely et al., 2005).<span>\u00a0 </span>The antiatherosclerotic mechanism has been called into question, but a number of other theories have been put forth to explain the supposed benefits from EDTA chelation.</p>\n<p class=\"MsoNormal\" style=\"text-indent:0.5in;\">\u00a0</p>\n<p class=\"MsoNormal\">Dr. Garry Gordon, a cofounder of the American College for Advancement in Medicine (ACAM), writer of \u201cThe Chelation Answer,\u201d and a major innovator of modern chelation therapy, submits that lead, mercury, and cadmium are present in high levels in the body as a result of life in industrial society (Brown, 2007).<span>\u00a0 </span>A recent report observes an association between blood lead levels<sup> </sup>and increased cardiovascular and all-cause mortality among groups of comparable socioeconomic status and racial composition even when people with levels about 0.48 ug/L were excluded (Menke et al., 2006).<span>\u00a0 </span>Gordon points out that lead inhibits the synthesis of nitric oxide, which helps to improve blood flow and enhance circulation.<span>\u00a0 </span>Indeed, lead has been shown to inhibit an isoform of nitric oxide synthase (Mittal et al., 2000), and inhibition of the endothelial isoform of this enzyme has been linked to increased atherosclerosis in rabbits (Cayette et al., 1994).<span>\u00a0 </span>Dr. Gordon holds that oral and/or intravenous EDTA can lead to overall well-being by eliminating these metals, leading to \u201cfewer infections in childhood\u201d and \u201cless death and longer lifespans.\u201d<span>\u00a0 </span>He goes on to state that \u201cmany [EDTA-treated] people still find that their memory improves, their sex life gets better, their feet get warmer, their blood pressure grows more normal, and they can suddenly run upstairs\u201d (Brown, 2007).<span>\u00a0 </span></p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">In \u201cBypassing Bypass Surgery,\u201d Dr. Elmer Cranton defends chelation and identifies flaws in recent clinical studies which claim to show no benefit from chelation therapy.<span>\u00a0 </span>He alleges that pharmaceutical and vascular surgery interests work to obscure positive findings on this therapy.<span>\u00a0 </span>To support his claims, Cranton references many of the articles cited in this report, as well as numerous articles in the \u201cJournal for Advancement in Medicine,\u201d which is not available at the National Library of Medicine or most medical libraries (Cranton, 2005).</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">Today, alternative use of intravenous chelation therapy is estimated to account for more than $400 million spent annually in the U.S. (Knudson et al., 2002).<span>\u00a0 </span>Chelation courses vary, but those detailed in this report consist of 20-33 intravenously administered solutions of 3 g or 40 mg/kg disodium EDTA delivered over 3 hours in 500 ml normal saline over 10 weeks to 6 months (Kitchell et al., 1963; Olszewer et al, 1990; Guldager et al., 1992; van Rij et al., 1994; Knudson et al., 2002).<span>\u00a0\u00a0 </span>This is often accompanied with varying levels of ascorbic acid, B-vitamins, heparin, and the minerals magnesium, copper, zinc, selenium and manganese (Seely et al., 2005).<span>\u00a0 </span></p>\n<p class=\"MsoNormal\"><em>\u00a0</em></p>\n<p class=\"MsoNormal\"><em>Randomized, double blind, placebo controlled studies for intravenous chelation</em></p>\n<p class=\"MsoNormal\">A total of five distinct randomized, placebo controlled, double blind clinical trials of intravenous EDTA chelation therapy use have been conducted to date, and they sought to test specific cardiovascular outcomes of patients.<span>\u00a0 </span>The first such trial to suggest some improvement in cardiovascular performance after EDTA therapy was reported in 1963.<span>\u00a0 </span>The study included 4 patients undergoing chelation and 5 being treated with a placebo.<span>\u00a0 </span>Two of the members of the chelation group exhibited improved subjective markers and ECG readings after 12 weeks, compared with none from the placebo group, and the trial was halted at this point because 3 of 5 of the placebo group members dropped out.<span>\u00a0 </span>Despite earlier enthusiasm, the authors of the study determined that ECG and subjective markers do not actually correlate with cardiovascular health and drew no valid conclusions from this study.<span>\u00a0 </span>They also expressed skepticism about successful cases that they reported earlier with patients using chelation (Kitchell et al., 1963).</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">A trial in 1990 examined 10 patients with peripheral vascular disease undergoing either a chelation or placebo course shows the most positive results for chelation therapy.<span>\u00a0 </span>After 10 weeks of therapy, chelation patients experienced about a two-fold increase in walking distance, masters steps, and bicycling times, whereas the five placebo patients experienced essentially no change.<span>\u00a0 </span>The authors unblinded themselves at this point and administered chelation to all patients (Olszewer et al., 1990).<span>\u00a0 </span>A meta-analysis performed in 1993 on 19 articles added to the chelation therapy enthusiasm by reporting a high statistical correlation coefficient of 0.88 between use of chelation and cardiovascular benefit for 22,765 patients covered in the analysis (Chappell et al., 1993).<span>\u00a0 </span></p>\n<p class=\"MsoNormal\"><em>\u00a0</em></p>\n<p class=\"MsoNormal\">Beginning more than a decade ago, several studies concluded that chelation therapy does not improve atherosclerosis.<span>\u00a0 </span>A Danish study reported in 1992 refutes the ability of intravenous chelation therapy to treat intermittent claudication (IC), a cramping sensation in the legs attributed to severe atherosclerosis.<span>\u00a0 </span>This study looked at the ability of chelation to affect changes in 153 patients suffering from IC.<span>\u00a0 </span>Chelation or placebo was administered for 5-9 weeks.<span>\u00a0 </span>The authors report that no significant changes in diagnostic markers for IC, including as maximal walking distance, pain-free walking distance, and ankle/brachial pulse ratio, were similar in both groups (Guldager et al., 1992).<span>\u00a0 </span></p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">Analysis of biochemical markers in a subset of 54 participants from both arms of this study suggest that chelation therapy influences the calcium-parathyroid hormone (PTH) axis to affect bone resorption.<span>\u00a0 </span>The chelation group, but not the placebo group, experienced an increase in calcium excretion in the urine evidenced by increased urinary calcium/creatine ratios, a 2 \u00bd fold increase in serum PTH levels, and a decrease in serum phosphate levels.<span>\u00a0\u00a0 </span>Analysis of biochemical markers for bone turnover showed that an increase in OH-proline/creatine ratios in the urine correlated with the change in urinary calcium/creatinine ratio in the chelation group, but not the placebo group, after treatment.<span>\u00a0 </span>Serum alkaline phosphatase activity increased in the chelation group during this time.<span>\u00a0\u00a0 </span>Together, these findings suggest that EDTA elevates PTH release by increasing calcium clearance, which leads to increased bone loss via resorption (Guldager et al., 1993).</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">Cranton identifies major flaws in the conclusions drawn by these authors by calling attention to an unusual discrepancy between maximal walking distances between study arms before treatment: 119 meters compared to 157 meters for the chelation and placebo arms, respectively.<span>\u00a0 </span>He also points out a suspiciously high standard deviation for maximal walking distance before treatment in the placebo group: 38 meters for the chelation group and 266 meters in the placebo group. <span>\u00a0</span>In addition to this, he interprets the 51% maximum walking distance improvement of the chelation group, compared to the 24% improvement of the placebo group, as a significant benefit from therapy.<span>\u00a0 </span>He also notes that the study focused on more than 80% smokers, which he claims hampers the effects of EDTA.<span>\u00a0 </span>Final criticisms are the high drop-out rate in this study, as 123 of 153 patients completed the 6-month follow-up, and the small size of the subset used to look at PTH-related markers.<span>\u00a0 </span>He holds that these flaws represent deliberate attempts by the Danish vascular surgeons running the study to hide the benefit of EDTA in order to prevent funding for a larger clinical trial, which might introduce chelation as a competitor to coronary bypass surgery (Cranton, 2005).</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">A double blind, placebo controlled study conducted in New Zealand and reported in 1994 looked at 32 patients, also with IC.<span>\u00a0 </span>These patients were treated with intravenous chelation or placebo for 10 weeks, and no significant differences were found in pain-free walking distance and maximal walking distance which are diagnostic markers for IC.<span>\u00a0 </span>Furthermore, lifestyle and subjective parameters of improvement, cardiac function, ECG, renal function, hematology, blood glucose, and lipid biochemistry showed no significant differences between groups.<span>\u00a0 </span>Among 18 subjective parameters, a significant difference between the chelation and placebo groups was reported in the increase in level of moderate exercise and the increase in level of physical activity relative to self, with the chelation group the benefits.<span>\u00a0 </span>The authors conclude that chelation does not provide benefits for patients with periphipheral vascular disease (van Rij et al., 1994).</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">Though the mechanism of antiatherosclerotic activity had largely been refuted at this point, enthusiasm for intravenous chelation therapy persisted and other mechanisms were speculated to account for cardiovascular benefits observed in case studies.<span>\u00a0 </span>In a 2002 report on the Canadian PATCH trial, no improvement in exercise capacity and quality of life was derived from chelation therapy for ischemic heart disease patients.<span>\u00a0 </span>This double blind, placebo controlled study placed 82 subjects on EDTA or placebo infusions over 6 months.<span>\u00a0 </span>After that time, no significant differences between drug and placebo were shown in time to 1 mm ST elevation on a treadmill or in several quality of life surveys including the Duke Activity Status Index (Knudson et al., 2002).<span>\u00a0 </span></p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">Cranton refers to a critique that asserts flaws in many aspects of the design and reporting of the PATCH trial.<span>\u00a0 </span>Most notable were the fact that 20 patients with previous myocardial infarction were randomized to the chelation arm and only 12 to the placebo arm; more antianginal-medicated patients randomized to the placebo arm than chelation arm, for instance 19 nitrate-taking patients were put in the placebo group and only 10 in the chelation group; modifications in the specific protocol to assess ischemic heart disease from published protocols, for instance changing treadmill intensity every 10 to 15 seconds instead of every 30 to 60 seconds.<span>\u00a0 </span>He also notes that 4 of the placebo patients and none of the chelation patients underwent angioplasty during the one year follow up after the trial as a possible success from chelation treatment (Olmstead, 2007).<span>\u00a0 </span></p>\n<p class=\"MsoNormal\"><em>\u00a0</em></p>\n<p class=\"MsoNormal\"><em>Oral chelation</em></p>\n<p class=\"MsoNormal\">A dearth of medical literature exists to describe oral chelation therapy, though several uses for oral ingestion of EDTA have been documented.<span>\u00a0 </span>EDTA has been shown to act as an antioxidant and effective preservative in foods (Jacobsen et al., 2001).<span>\u00a0 </span>As reduced iron disodium EDTA, it has been shown to enhance iron uptake compared to reduced iron alone (Fairweather-Tait et al., 2001), but studies in rats found iron sulfate more effective for this purpose than iron EDTA (Appel et al., 2001).<span>\u00a0 </span></p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">Dr. Gordon advises that \u201ceverybody needs to be doing the oral [EDTA] every day of their life\u201d (Brown, 2007).<span>\u00a0 </span>Noting that EDTA probably does not mitigate atherosclerosis as he originally thought, he suggests that the drug acts as an overall promoter of longevity through nitric oxide-related mechanisms described above, rather than a mediator of short-term cardiovascular improvements.</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">Cardio Chelate is an example of an oral EDTA formulation that can be purchased online without a prescription (AllChelation.com).<span>\u00a0 </span>Described as a dietary supplement, package information lists each pill containing 400 mg Calcium EDTA, 40 mg ascorbic acid, 40 mg methylsulfomethane, and 50 mg N-acetyl cysteine as ingredients.<span>\u00a0 </span>6 pills (2400 mg) are recommended daily, for instance 3 pills twice daily on an empty stomach.<span>\u00a0 </span>The container claims that 5% of orally administered EDTA is absorbed in the gut (AllChelation.com), which would result in a two- to three-fold lower effective intake of the oral formulation compared to a once-weekly 3 g intravenous formulation.</p>\n<p class=\"MsoNormal\" style=\"text-indent:0.5in;\">\u00a0</p>\n<p class=\"MsoNormal\">A survey of online oral EDTA-promoting websites (AllChelation.com, Life-enhancement.com, gordonresearch.com) reveals sites eager to put forth scientific evidence while often misrepresenting data.<span>\u00a0 </span>An example of this is found at <a href=\"http://www.life-enhancement.com\" rel=\"nofollow\">http://www.life-enhancement.com</a>:</p>\n<p class=\"MsoNormal\" style=\"margin:0 0.25in 0.0001pt;\"><em>According to one study published in the New England Journal of Medicine, \u201cAs compared with medical therapy, coronary artery bypass surgery appears neither to prolong life nor to prevent myocardial infarction in patients who have mild angina or who are asymptomatic after infarction in the five-year period after coronary angiography.\u201d By contrast, mortality rates for EDTA chelation, when carried out according to accepted protocols, approaches 0%.</em></p>\n<p class=\"MsoNormal\">Here, the quotation showing no benefit from a procedure for a particular set of patients is probably taken out of context to suggest that the treatment is generally ineffective.<span>\u00a0 </span>Another feature of the surveyed sites is the listing scientific sources that they claim support EDTA therapy.<span>\u00a0 </span>In fact, of more than 500 sources listed at <a href=\"http://www.gordonresearch.com\" rel=\"nofollow\">http://www.gordonresearch.com</a>, most were published before 1980, and many deal with properties of EDTA not related to cardiovascular function, such as food preservation and treatment of lead poisoning (gordonresearch.com).<span>\u00a0 </span>A retrospective study of oral EDTA use might shed some preliminary light on the effects of this therapy.</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\"><em>Possible Adverse Effects</em></p>\n<p class=\"MsoNormal\">12 cases of hypocalcemia in EDTA subjects and 1 in placebo subjects were reported in the 1993 study of 153 patients, in addition to the aforementioned bone loss (Guldager et al., 1992; Guldager et al., 1993).<span>\u00a0 </span>In the Knudson et al. study, one subject of 82 experienced rising creatinine levels that could not be attributed to anything other than the chelation therapy infusions (Knudson et al., 2002), suggesting that chelation could cause renal toxicity.<span>\u00a0 </span>A recent review of the literature hypothesizes that potential adverse effects not reported in controlled trials could include seizure and death as a result of hypocalcemia, heart failure as a result of fluid overload, elevated liver function tests, and hypoglycemia in insulin-requiring patients with diabetes (Lamas and Hussein, 2006).<span>\u00a0 </span>One may also speculate that EDTA levels could have adverse interactions with any drugs or diets that alter heavy metal metabolism, and it is probably important to take trace mineral supplements to help replace calcium, zinc, manganese, and other metals cleared by EDTA.</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">Literature does not exist to rule out the possibility of adverse reactions associated with oral chelation therapy, for instance disruption of metal metabolism and absorption in the gastrointestinal tract.<span>\u00a0 </span>Only anecdotal evidence exists to suggest that long-term administration of this drug is safe.<span>\u00a0 </span>Given the case of possible renal toxicity after several weeks of intravenous EDTA therapy, renal pathology associated with long term use is a potential serious adverse effect.<span>\u00a0 </span>Another consideration for this therapy is that it would result in chronic low levels of plasma EDTA, whereas a weekly injection which would introduce high levels of EDTA that would be effectively cleared in less than a day.<span>\u00a0 </span></p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\"><em>Future Studies</em></p>\n<p class=\"MsoNormal\">The Trial to Assess Chelation Therapy (TACT) is a randomized, double blind, placebo controlled trial that may provide more robust evidence for or against chelation therapy (Lamas and Hussein, 2007).<span>\u00a0 </span>It will enroll patients 50 years of age or older with a prior myocardial infarction.<span>\u00a0 </span>TACT aims to test the results of 40 infusions of an ACAM-recommended intravenous chelation solution, high-dose oral antioxidant vitamin and mineral supplements, and the combination of both for their effects on all-cause mortality, non-fatal myocardial infarction, non-fatal stroke, coronary revascularization, and hospitalization for angina.<span>\u00a0 </span>The study is expected to be completed in July 2009.</p>\n<p class=\"MsoNormal\"><em>\u00a0</em></p>\n<p class=\"MsoNormal\"><em>Comments</em></p>\n<p class=\"MsoNormal\">The five clinical trials described here provide robust information on the effectiveness of intravenous chelation therapy.<span>\u00a0 </span>A comparison of the number of subjects in each trial, in addition to the design of each study, suggests that chelation therapy does not lead to a significant benefit in the cardiovascular parameters tested.</p>\n<p class=\"MsoNormal\" style=\"text-indent:0.5in;\">\u00a0</p>\n<p class=\"MsoNormal\">Proposed mechanisms for the action of EDTA to improve health are rational, and one may speculate that chelation therapy could lead to long-term benefits described by Dr. Gordon that are not resolved in these shorter-term studies.<span>\u00a0 </span>Additionally, these studies may have looked at too few subjects to reveal the benefits of chelation.<span>\u00a0 </span>For instance, the Knudson et al. study of 82 subjects only provided a 90% power to detect a 60-second difference in change in time to ST-elevation (Knudson et al., 2002).<span>\u00a0 </span></p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">Most patients were no worse off with EDTA than with placebo.<span>\u00a0 </span>However, rare adverse events in clinical trials indicate that chelation should be administered while closely monitoring serum creatinine, calcium, and PTH.<span>\u00a0 </span>One can reason that oral EDTA would be safer than the intravenous form due to the lower dosage and non-invasive administration.<span>\u00a0 </span>However, similar caution seems prudent given theoretical adverse reactions and the lack of clinical experience with this route of administration.<span>\u00a0 </span>Clearly, studies enrolling more subjects, looking at longer-term endpoints, and analyzing both oral and intravenous administration would help to evaluate chelation as a mediator of general well-being and life extension.<span>\u00a0 </span></p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">Overall, evidence for short-term cardiovascular benefit from chelation therapy is unconvincing.<span>\u00a0 </span>Adverse effects of such therapy are likely to be minimal, but caution is important given theoretical adverse reactions pointed out by others.<span>\u00a0 </span>Though benefits heralded by chelation enthusiasts cannot be substantiated at this time, it is possible that such health benefits will be borne out by further investigations, including the TACT therapy study that is currently underway.</p>\n<p class=\"MsoNormal\" style=\"text-align:right;\" align=\"right\">\u00a0</p>\n<p><span style=\"font-size:12pt;font-family:'Times New Roman';\"><br /> </span></p>\n<p class=\"MsoNormal\" style=\"text-align:center;\" align=\"center\">References</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">Habal R, Talavera F, Sharma OP, Rice TD, Pinksy MR.<span>\u00a0 </span>Toxicity, Lead.<span>\u00a0 </span>eMedicine 2006.<span>\u00a0 </span>Available at: &lt;<a href=\"http://www.emedicine.com/med/topic1269.htm&#038;gt\" rel=\"nofollow\">http://www.emedicine.com/med/topic1269.htm&#038;gt</a>; (cited: 11 June 2007)</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">Klasco RK (Ed): DRUGDEX\u00ae System (electronic version). Thomson Klasco, 2007,</p>\n<p class=\"MsoNormal\">Greenwood Village,  Colorado, USA. Available at: &lt;<a href=\"http://micromedex.duhs.duke.edu/hcs/librarian/ND_PR/Main/PFPUI/EGzU5I1UCfa5i/ND_PG/PRIH/CS/0F816F/ND_T/HCS/ND_P/Main/DUPLICATIONSHIELDSYNC/BF55C1/ND_B/HCS/PFActionId/hcs.common.RetrieveDocumentCommon/DocId/1215/ContentSetId/31#all&#038;gt\" rel=\"nofollow\">http://micromedex.duhs.duke.edu/hcs/librarian/ND_PR/Main/PFPUI/EGzU5I1UCfa5i/ND_PG/PRIH/CS/0F816F/ND_T/HCS/ND_P/Main/DUPLICATIONSHIELDSYNC/BF55C1/ND_B/HCS/PFActionId/hcs.common.RetrieveDocumentCommon/DocId/1215/ContentSetId/31#all&#038;gt</a>; (cited: 11 June 2007).</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">Clarke NE, Clarke CN, Mosher RE. The in vivo dissolution of metastatic calcium; an approach to atherosclerosis. Am J Med Sci 1955;229:142\u20139.</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">Clarke CN, Clarke  NE, Mosher RE. Treatment of angina pectoris with disodium ethylene diamine tetraacetic acid.<span>\u00a0 </span>Am J Med Sci 1956;232:654\u201366.</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">Seely DMR, Wu P, Mills EJ.<span>\u00a0 </span>EDTA chelation therapy for cardiovascular disease: a systematic review.<span>\u00a0 </span>BMB CV Disorders 2005; 5:32</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">Mittal CK, Harrell WB, Mehta CS.<span>\u00a0 </span>Interaction of heavy metal toxicants with brain constitutive nitric oxide synthase.<span>\u00a0 </span>Biol Trace Elem Res 2000; 77(2):97-106<span style=\"font-family:'AdvTTda6f6cb8.B';\"></span></p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">Cayatte AJ, Palacino JJ, Horten K, Cohen-RA. Chronic inhibition of nitric oxide production accelerates neointima formation and impairs endothelial function in hypercholesterolemic rabbits. Arterioscler Thromb. 1994;14: 753\u2013759.</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">Brown, DJ.<span>\u00a0 </span>\u201cElation over chelation: an interview with Dr. Garry Gordon.\u201d<span>\u00a0 </span>Mavericks of medicine: conversations on the frontiers of medical research.<span>\u00a0 </span>Petaluma, CA: Smart Publications 2007 45-61</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">Menke A, Muntner P, Batuman V, Silbergeld EK, Guallar E.<span>\u00a0 </span>Blood Lead Below 0.48 \u03bcmol/L (10 \u03bcg/dL) and Mortality Among US Adults.<span>\u00a0 </span>Circulation<em> </em>2006;114:1388-1394<span style=\"font-size:10pt;\"></span></p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">Cranton, EM.<span>\u00a0 </span>\u201cA summary of EDTA chelation clinical research: all good!\u201d<span>\u00a0 </span>Bypassing bypass surgery.<span>\u00a0 </span>2005.</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">Kitchell JR, Palmon FJ, Aytan N, Meltzer LE: The treatment of coronary artery disease with disodium EDTA. A reappraisal. Am J Cardiol 1963, 11:501-506.</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">Olszewer E, Sabbag FC, Carter JP: A pilot double blind study of sodium-magnesium EDTA in peripheral vascular disease.<span>\u00a0 </span>J Natl Med Assoc 1990, 82(3):173-177.</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">van Rij AM, Solomon C, Packer SG, Hopkins WG. Chelation therapy for intermittent claudication. A double blind, randomized, controlled trial. Circulation 1994;90:1194\u20139.</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">Guldager B, Jelnes R, J\u00f8rgensen SJ, Nielsen JS, Klaerke A, Mogensen K, Larsen KE, Reimer E, Holm J, Ottesen S.<span>\u00a0 </span>EDTA treatment of intermittent claudication&#8211;a double blind, placebo controlled study.<span>\u00a0 </span>J Intern Med. 1992;231:261-267.</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">Knudtson ML, Wyse DG, Galbraith PD. <span>\u00a0</span>Chelation therapy for ischemic heart disease: a randomized controlled trial. J Am Med Assoc 2002; 287:481\u20136.</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">Chappell LT, Stahl JP: The correlation between EDTA chelation therapy and improvement in cardiovascular function: a meta-analysis. J Adv Med 1993, 6:139-160.</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">Guldager B, Brixen KT, Jorgensen SJ, Nielsen HK, Mosekilde L, Jelnes R. Effects of intravenous EDTA treatment on serum parathyroid hormone (1\u201384) and biochemical markers of bone turnover. Dan Med Bull 1993;40:627\u201330.</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">Olmstead, SF.<span>\u00a0 </span>\u201cCritique of the <a name=\"PATCH\"></a>PATCH Chelation Therapy Trial.\u201d<span>\u00a0 </span>Mount Rainer Clinic.<span>\u00a0 </span>2007.<span>\u00a0 </span>Available at &lt;<a href=\"http://www.drcranton.com/sham.htm\">http://www.drcranton.com/sham.htm</a>&gt;.<span>\u00a0 </span>(cited June 13, 2007).</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">Jacobsen C, Hartvigsen K, Thomsen MK, Hansen LF, Lund P, Skibsted LH, Holmer G, Adler-Nissen J, Meyer AS. Lipid oxidation in fish oil enriched mayonnaise: calcium disodium ethylenediaminetetraacetate, but not gallic acid, strongly inhibited oxidative deterioration. J Agric. Food Chem. 2001; 49(2):1009-1019.</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">Fairweather-Tait SJ, Wortley GM, Teucher B, Dainty J. Iron absorption from a breakfast cereal: effects of EDTA compounds and ascorbic acid. Int. J Vitam. Nutr. Res. 2001; 71(2):117-122.</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">Appel MJ, Kuper CF, Wouteren RA (Dept of General Toxicology, TNO Nutrition and Food Research, Zeist, Neth.). 352654b Disposition, accumulation and toxicity of iron fed as iron (II) sulfate or as sodium iron EDTA in rats. Food Chem. Toxicol. 2001; 39(3):261-269.</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">AllChelation.com.<span>\u00a0 </span>2007.<span>\u00a0 </span>Available at &lt;www.allchelation.com&gt; (cited: 11 June 2007).</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u201cEDTA Chelation.<span>\u00a0 </span>The real \u201cmiracle\u201d therapy for vascular disease.\u201d<span>\u00a0 </span>Life-enhancement.com. <span>\u00a0</span>2007. <span>\u00a0</span>Available at &lt;<a href=\"http://www.life-enhancement.com/article_template.asp?ID=78&#038;gt\" rel=\"nofollow\">http://www.life-enhancement.com/article_template.asp?ID=78&#038;gt</a>;<span>\u00a0 </span>(cited: 12 June 2007)</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u201cOral Chelation.\u201d<span>\u00a0 </span>Gordon Research Institute.<span>\u00a0 </span>2001.<span>\u00a0 </span>Available at &lt;<a href=\"http://www.gordonresearch.com/category_oral_chelation.html&#038;gt\" rel=\"nofollow\">http://www.gordonresearch.com/category_oral_chelation.html&#038;gt</a>; (cited: 12 June 2007).</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">Lamas GA and Hussein SJ.<span>\u00a0 </span>EDTA chelation therapy meets evidence-based medicine.<span>\u00a0 </span>Comp Ther in Clin Practice 2006; <span style=\"font-family:'AdvTTda6f6cb8.B';\">12</span><span style=\"font-family:AdvTTc9c3bd71;\">:213</span><span style=\"font-family:AdvMacT_R;\">\u2013</span><span style=\"font-family:AdvTTc9c3bd71;\">215</span></p>\n<div id=\"jp-post-flair\" class=\"sharedaddy sd-like-enabled\"><div class='sharedaddy sd-block sd-like jetpack-likes-widget-wrapper jetpack-likes-widget-unloaded' id='like-post-wrapper-1243944-10-581e997fe4a03' data-src='//widgets.wp.com/likes/#blog_id=1243944&amp;post_id=10&amp;origin=chelate.wordpress.com&amp;obj_id=1243944-10-581e997fe4a03' data-name='like-post-frame-1243944-10-581e997fe4a03'><h3 class='sd-title'>Like this:</h3><div class='likes-widget-placeholder post-likes-widget-placeholder' style='height: 55px;'><span class='button'><span>Like</span></span> <span class=\"loading\">Loading...</span></div><span class='sd-text-color'></span><a class='sd-link-color'></a></div></div>\n\t\t\t\t\n\t\t\t</div>\n\t\t</div>\n\t  \t\n\t<div id=\"comments\">\n\n\n\n\n\t\t\t\t<div id=\"respond\" class=\"comment-respond\">\n\t\t\t<h3 id=\"reply-title\" class=\"comment-reply-title\">Leave a Reply <small><a rel=\"nofollow\" id=\"cancel-comment-reply-link\" href=\"/report/#respond\" style=\"display:none;\">Cancel reply</a></small></h3>\t\t\t\t<form action=\"https://chelate.wordpress.com/wp-comments-post.php\" method=\"post\" id=\"commentform\" class=\"comment-form\">\n\t\t\t\t\t<input type=\"hidden\" id=\"highlander_comment_nonce\" name=\"highlander_comment_nonce\" value=\"ca9d3aff8f\" /><input type=\"hidden\" name=\"_wp_http_referer\" value=\"/report/\" />\n<input type=\"hidden\" name=\"hc_post_as\" id=\"hc_post_as\" value=\"guest\" />\n\n<div class=\"comment-form-field comment-textarea\">\n\t<label for=\"comment\">Enter your comment here...</label>\n\t<div id=\"comment-form-comment\"><textarea id=\"comment\" name=\"comment\" title=\"Enter your comment here...\"></textarea></div>\n</div>\n\n<div id=\"comment-form-identity\">\n\n\t<div id=\"comment-form-nascar\">\n\t\t<p>Fill in your details below or click an icon to log in:</p>\n\t\t<ul>\n\t\t\t<li class=\"selected\" style=\"display:none;\">\n\t\t\t\t<a href=\"#comment-form-guest\" id=\"postas-guest\" title=\"Guest\">\n\t\t\t\t\t<span></span>\n\t\t\t\t</a>\n\t\t\t</li>\n\t\t\t<li>\n\t\t\t\t<a href=\"#comment-form-load-service:WordPress.com\" id=\"postas-wordpress\" title=\"WordPress.com\">\n\t\t\t\t\t<span></span>\n\t\t\t\t</a>\n\t\t\t</li>\n\t\t\t<li>\n\t\t\t\t<a href=\"#comment-form-load-service:Twitter\" id=\"postas-twitter\" title=\"Twitter\">\n\t\t\t\t\t<span></span>\n\t\t\t\t</a>\n\t\t\t</li>\n\t\t\t<li>\n\t\t\t\t<a href=\"#comment-form-load-service:Facebook\" id=\"postas-facebook\" title=\"Facebook\">\n\t\t\t\t\t<span></span>\n\t\t\t\t</a>\n\t\t\t</li>\n\t\t\t<li>\n\t\t\t<iframe id=\"googleplus-sign-in\" name=\"googleplus-sign-in\" src=\"https://public-api.wordpress.com/connect/?googleplus-sign-in=https%3A%2F%2Fchelate.wordpress.com\" width=\"24\" height=\"24\" scrolling=\"no\" allowtransparency=\"true\" seamless=\"seamless\" frameborder=\"0\"></iframe>\n\t\t\t</li>\n\t\t</ul>\n\t</div>\n\n\t<div id=\"comment-form-guest\" class=\"comment-form-service selected\">\n\t\t<div class=\"comment-form-padder\">\n\t\t\t<div class=\"comment-form-avatar\">\n<a href=\"https://gravatar.com/site/signup/\" target=\"_blank\">\t\t\t\t<img src=\"https://1.gravatar.com/avatar/ad516503a11cd5ca435acc9bb6523536?s=25&amp;d=identicon&amp;forcedefault=y\" alt=\"Gravatar\" width=\"25\" class=\"no-grav\" />\n</a>\t\t\t</div>\n\n\t\t\t\t<div class=\"comment-form-fields\">\n\t\t\t\t<div class=\"comment-form-field comment-form-email\">\n\t\t\t\t\t<label for=\"email\">Email <span class=\"required\">(required)</span> <span class=\"nopublish\">(Address never made public)</span></label>\n\t\t\t\t\t<div class=\"comment-form-input\"><input id=\"email\" name=\"email\" type=\"email\" value=\"\" /></div>\n\t\t\t\t</div>\n\t\t\t\t<div class=\"comment-form-field comment-form-author\">\n\t\t\t\t\t<label for=\"author\">Name <span class=\"required\">(required)</span></label>\n\t\t\t\t\t<div class=\"comment-form-input\"><input id=\"author\" name=\"author\" type=\"text\" value=\"\" /></div>\n\t\t\t\t</div>\n\t\t\t\t<div class=\"comment-form-field comment-form-url\">\n\t\t\t\t\t<label for=\"url\">Website</label>\n\t\t\t\t\t<div class=\"comment-form-input\"><input id=\"url\" name=\"url\" type=\"text\" value=\"\" /></div>\n\t\t\t\t</div>\n\t\t\t</div>\n\t\n\t\t</div>\n\t</div>\n\n\t<div id=\"comment-form-wordpress\" class=\"comment-form-service\">\n\t\t<div class=\"comment-form-padder\">\n\t\t\t<div class=\"comment-form-avatar\">\n\t\t\t\t<img src=\"https://1.gravatar.com/avatar/ad516503a11cd5ca435acc9bb6523536?s=25&amp;d=identicon&amp;forcedefault=y\" alt=\"WordPress.com Logo\" width=\"25\" class=\"no-grav\" />\n\t\t\t</div>\n\n\t\t\t\t<div class=\"comment-form-fields\">\n\t\t\t\t<input type=\"hidden\" name=\"wp_avatar\" id=\"wordpress-avatar\" class=\"comment-meta-wordpress\" value=\"\" />\n\t\t\t\t<input type=\"hidden\" name=\"wp_user_id\" id=\"wordpress-user_id\" class=\"comment-meta-wordpress\" value=\"\" />\n\t\t\t\t<input type=\"hidden\" name=\"wp_access_token\" id=\"wordpress-access_token\" class=\"comment-meta-wordpress\" value=\"\" />\n\t\t\t\t<p class=\"comment-form-posting-as pa-wordpress\"><strong></strong> You are commenting using your WordPress.com account. <span class=\"comment-form-log-out\">(&nbsp;<a href=\"javascript:HighlanderComments.doExternalLogout( 'wordpress' );\">Log&nbsp;Out</a>&nbsp;/&nbsp;<a href=\"#\" onclick=\"javascript:HighlanderComments.switchAccount();return false;\">Change</a>&nbsp;)</span></p>\n\t\t\t</div>\n\t\n\t\t</div>\n\t</div>\n\n\t<div id=\"comment-form-twitter\" class=\"comment-form-service\">\n\t\t<div class=\"comment-form-padder\">\n\t\t\t<div class=\"comment-form-avatar\">\n\t\t\t\t<img src=\"https://1.gravatar.com/avatar/ad516503a11cd5ca435acc9bb6523536?s=25&amp;d=identicon&amp;forcedefault=y\" alt=\"Twitter picture\" width=\"25\" class=\"no-grav\" />\n\t\t\t</div>\n\n\t\t\t\t<div class=\"comment-form-fields\">\n\t\t\t\t<input type=\"hidden\" name=\"twitter_avatar\" id=\"twitter-avatar\" class=\"comment-meta-twitter\" value=\"\" />\n\t\t\t\t<input type=\"hidden\" name=\"twitter_user_id\" id=\"twitter-user_id\" class=\"comment-meta-twitter\" value=\"\" />\n\t\t\t\t<input type=\"hidden\" name=\"twitter_access_token\" id=\"twitter-access_token\" class=\"comment-meta-twitter\" value=\"\" />\n\t\t\t\t<p class=\"comment-form-posting-as pa-twitter\"><strong></strong> You are commenting using your Twitter account. <span class=\"comment-form-log-out\">(&nbsp;<a href=\"javascript:HighlanderComments.doExternalLogout( 'twitter' );\">Log&nbsp;Out</a>&nbsp;/&nbsp;<a href=\"#\" onclick=\"javascript:HighlanderComments.switchAccount();return false;\">Change</a>&nbsp;)</span></p>\n\t\t\t</div>\n\t\n\t\t</div>\n\t</div>\n\n\t<div id=\"comment-form-facebook\" class=\"comment-form-service\">\n\t\t<div class=\"comment-form-padder\">\n\t\t\t<div class=\"comment-form-avatar\">\n\t\t\t\t<img src=\"https://1.gravatar.com/avatar/ad516503a11cd5ca435acc9bb6523536?s=25&amp;d=identicon&amp;forcedefault=y\" alt=\"Facebook photo\" width=\"25\" class=\"no-grav\" />\n\t\t\t</div>\n\n\t\t\t\t<div class=\"comment-form-fields\">\n\t\t\t\t<input type=\"hidden\" name=\"fb_avatar\" id=\"facebook-avatar\" class=\"comment-meta-facebook\" value=\"\" />\n\t\t\t\t<input type=\"hidden\" name=\"fb_user_id\" id=\"facebook-user_id\" class=\"comment-meta-facebook\" value=\"\" />\n\t\t\t\t<input type=\"hidden\" name=\"fb_access_token\" id=\"facebook-access_token\" class=\"comment-meta-facebook\" value=\"\" />\n\t\t\t\t<p class=\"comment-form-posting-as pa-facebook\"><strong></strong> You are commenting using your Facebook account. <span class=\"comment-form-log-out\">(&nbsp;<a href=\"javascript:HighlanderComments.doExternalLogout( 'facebook' );\">Log&nbsp;Out</a>&nbsp;/&nbsp;<a href=\"#\" onclick=\"javascript:HighlanderComments.switchAccount();return false;\">Change</a>&nbsp;)</span></p>\n\t\t\t</div>\n\t\n\t\t</div>\n\t</div>\n\n\t<div id=\"comment-form-googleplus\" class=\"comment-form-service\">\n\t\t<div class=\"comment-form-padder\">\n\t\t\t<div class=\"comment-form-avatar\">\n\t\t\t\t<img src=\"https://1.gravatar.com/avatar/ad516503a11cd5ca435acc9bb6523536?s=25&amp;d=identicon&amp;forcedefault=y\" alt=\"Google+ photo\" width=\"25\" class=\"no-grav\" />\n\t\t\t</div>\n\n\t\t\t\t<div class=\"comment-form-fields\">\n\t\t\t\t<input type=\"hidden\" name=\"googleplus_avatar\" id=\"googleplus-avatar\" class=\"comment-meta-googleplus\" value=\"\" />\n\t\t\t\t<input type=\"hidden\" name=\"googleplus_user_id\" id=\"googleplus-user_id\" class=\"comment-meta-googleplus\" value=\"\" />\n\t\t\t\t<input type=\"hidden\" name=\"googleplus_access_token\" id=\"googleplus-access_token\" class=\"comment-meta-googleplus\" value=\"\" />\n\t\t\t\t<p class=\"comment-form-posting-as pa-googleplus\"><strong></strong> You are commenting using your Google+ account. <span class=\"comment-form-log-out\">(&nbsp;<a href=\"javascript:HighlanderComments.doExternalLogout( 'googleplus' );\">Log&nbsp;Out</a>&nbsp;/&nbsp;<a href=\"#\" onclick=\"javascript:HighlanderComments.switchAccount();return false;\">Change</a>&nbsp;)</span></p>\n\t\t\t</div>\n\t\n\t\t</div>\n\t</div>\n\n\n\t<div id=\"comment-form-load-service\" class=\"comment-form-service\">\n\t\t<div class=\"comment-form-posting-as-cancel\"><a href=\"javascript:HighlanderComments.cancelExternalWindow();\">Cancel</a></div>\n\t\t<p>Connecting to %s</p>\n\t</div>\n\n</div>\n\n<script type=\"text/javascript\">\nvar highlander_expando_javascript = function(){\n\tvar input = document.createElement( 'input' ),\n\t    comment = jQuery( '#comment' );\n\n\tif ( 'placeholder' in input ) {\n\t\tcomment.attr( 'placeholder', jQuery( '.comment-textarea label' ).remove().text() );\n\t}\n\n\t// Expando Mode: start small, then auto-resize on first click + text length\n\tjQuery( '#comment-form-identity' ).hide();\n\tjQuery( '#comment-form-subscribe' ).hide();\n\tjQuery( '#commentform .form-submit' ).hide();\n\n\tcomment.css( { 'height':'10px' } ).one( 'focus', function() {\n\t\tvar timer = setInterval( HighlanderComments.resizeCallback, 10 )\n\t\tjQuery( this ).animate( { 'height': HighlanderComments.initialHeight } ).delay( 100 ).queue( function(n) { clearInterval( timer ); HighlanderComments.resizeCallback(); n(); } );\n\t\tjQuery( '#comment-form-identity' ).slideDown();\n\t\tjQuery( '#comment-form-subscribe' ).slideDown();\n\t\tjQuery( '#commentform .form-submit' ).slideDown();\n\t});\n}\njQuery(document).ready( highlander_expando_javascript );\n</script>\n\n<div id=\"comment-form-subscribe\">\n\t<p class=\"comment-subscription-form\"><input type=\"checkbox\" name=\"subscribe\" id=\"subscribe\" value=\"subscribe\" style=\"width: auto;\"/> <label class=\"subscribe-label\" id=\"subscribe-label\" for=\"subscribe\" style=\"display: inline;\">Notify me of new comments via email.</label></p></div>\n\n\n\n\n<p class=\"form-submit\"><input name=\"submit\" type=\"submit\" id=\"comment-submit\" class=\"submit\" value=\"Post Comment\" /> <input type='hidden' name='comment_post_ID' value='10' id='comment_post_ID' />\n<input type='hidden' name='comment_parent' id='comment_parent' value='0' />\n</p><p style=\"display: none;\"><input type=\"hidden\" id=\"akismet_comment_nonce\" name=\"akismet_comment_nonce\" value=\"0855382b4d\" /></p>\n<input type=\"hidden\" name=\"genseq\" value=\"1478400383\" />\n<p style=\"display: none;\"><input type=\"hidden\" id=\"ak_js\" name=\"ak_js\" value=\"236\"/></p>\t\t\t\t</form>\n\t\t\t\t\t</div><!-- #respond -->\n\t\t<div style=\"clear: both\"></div>\n</div><!-- #comments -->\n\t</div>\n\n\t<div id=\"sidebar\">\n\t\t\t\t<ul>\n\n\t\t\t\t\t<li><h2>Archives</h2>\n\t\t\t\t<ul>\n\t\t\t\t\t<li><a href='https://chelate.wordpress.com/2007/06/'>June 2007</a></li>\n\t\t\t\t</ul>\n\t\t\t</li>\n\n\t\t\t<li><h2>Categories</h2>\n\t\t\t\t<ul>\n\t\t\t\t\t\t<li class=\"cat-item cat-item-273\"><a href=\"https://chelate.wordpress.com/category/blog/\" >Blog</a>\n</li>\n\t<li class=\"cat-item cat-item-103\"><a href=\"https://chelate.wordpress.com/category/news/\" >News</a>\n</li>\n\t<li class=\"cat-item cat-item-6976\"><a href=\"https://chelate.wordpress.com/category/studies/\" >Studies</a>\n</li>\n\t\t\t\t</ul>\n\t\t\t</li>\n\n\t\t\t\t\t\t\t\n\t\t\t\t<li><h2>Meta</h2>\n\t\t\t\t<ul>\n\t\t\t\t\t<li><a href=\"https://wordpress.com/start?ref=wplogin\">Register</a></li>\t\t\t\t\t<li><a href=\"https://chelate.wordpress.com/wp-login.php\">Log in</a></li>\n\t\t\t\t\t\t\t\t\t</ul>\n\t\t\t\t</li>\n\t\t\t\n\t\t</ul>\n\t</div>\n\n\n<div id=\"footer\">\n\t<p>\n\t<br />\n\t<a href=\"https://wordpress.com/?ref=footer_website\">Create a free website or blog at WordPress.com.</a>\n\t</p>\n</div>\n\n</div>\n\n\t\t<!--  -->\n\t<div style=\"display:none\">\n\t</div>\n<script type='text/javascript'>\n/* <![CDATA[ */\nvar HighlanderComments = {\"loggingInText\":\"Logging In\\u2026\",\"submittingText\":\"Posting Comment\\u2026\",\"postCommentText\":\"Post Comment\",\"connectingToText\":\"Connecting to %s\",\"commentingAsText\":\"%1$s: You are commenting using your %2$s account.\",\"logoutText\":\"Log Out\",\"loginText\":\"Log In\",\"connectURL\":\"https:\\/\\/chelate.wordpress.com\\/public.api\\/connect\\/?action=request\",\"logoutURL\":\"https:\\/\\/chelate.wordpress.com\\/wp-login.php?action=logout&_wpnonce=47d6335f8f\",\"homeURL\":\"https:\\/\\/chelate.wordpress.com\\/\",\"postID\":\"10\",\"gravDefault\":\"\",\"enterACommentError\":\"Please enter a comment\",\"enterEmailError\":\"Please enter your email address here\",\"invalidEmailError\":\"Invalid email address\",\"enterAuthorError\":\"Please enter your name here\",\"gravatarFromEmail\":\"This picture will show whenever you leave a comment. Click to customize it.\",\"logInToExternalAccount\":\"Log in to use details from one of these accounts.\",\"change\":\"Change\",\"changeAccount\":\"Change Account\",\"comment_registration\":\"\",\"userIsLoggedIn\":\"\",\"isJetpack\":\"0\",\"text_direction\":\"ltr\"};\n/* ]]> */\n</script>\n<script type='text/javascript' src='https://s0.wp.com/_static/??/wp-content/js/jquery/jquery.autoresize.js,/wp-content/mu-plugins/highlander-comments/script.js?m=1462457903j'></script>\n<script type='text/javascript' src='https://s1.wp.com/wp-content/mu-plugins/akismet-3.0/_inc/form.js?m=1404442431h'></script>\n<script type='text/javascript'>\n/* <![CDATA[ */\nvar actionbardata = {\"siteID\":\"1243944\",\"siteName\":\"EDTA Chelation: A Factual Blog\",\"siteURL\":\"http:\\/\\/chelate.wordpress.com\",\"icon\":\"<img alt='' src='https:\\/\\/s1.wp.com\\/i\\/void.gif' class='avatar avatar-36' height='36' width='36' \\/>\",\"canManageOptions\":\"\",\"canCustomizeSite\":\"\",\"isFollowing\":\"\",\"themeSlug\":\"pub\\/contempt\",\"signupURL\":\"https:\\/\\/wordpress.com\\/start\\/\",\"loginURL\":\"https:\\/\\/chelate.wordpress.com\\/wp-login.php?redirect_to=https%3A%2F%2Fchelate.wordpress.com%2Freport%2F\",\"themeURL\":\"\",\"xhrURL\":\"https:\\/\\/chelate.wordpress.com\\/wp-admin\\/admin-ajax.php\",\"nonce\":\"9a75d01e08\",\"isSingular\":\"1\",\"isFolded\":\"\",\"isLoggedIn\":\"\",\"isMobile\":\"\",\"subscribeNonce\":\"<input type=\\\"hidden\\\" id=\\\"_wpnonce\\\" name=\\\"_wpnonce\\\" value=\\\"bf4c124db1\\\" \\/>\",\"referer\":\"https:\\/\\/chelate.wordpress.com\\/report\\/\",\"canFollow\":\"1\",\"statusMessage\":\"\",\"customizeLink\":\"https:\\/\\/chelate.wordpress.com\\/wp-admin\\/customize.php?url=https%3A%2F%2Fchelate.wordpress.com%2Freport%2F\",\"postID\":\"10\",\"shortlink\":\"http:\\/\\/wp.me\\/P5dBC-a\",\"canEditPost\":\"\",\"editLink\":\"https:\\/\\/wordpress.com\\/page\\/chelate.wordpress.com\\/10\",\"i18n\":{\"view\":\"View Site\",\"follow\":\"Follow\",\"following\":\"Following\",\"edit\":\"Edit\",\"login\":\"Log In\",\"signup\":\"Sign Up\",\"customize\":\"Customize\",\"report\":\"Report this content\",\"themeInfo\":\"Get theme: Contempt\",\"shortlink\":\"Copy shortlink\",\"copied\":\"Copied\",\"followedText\":\"New posts from this site will now appear in your <a href=\\\"https:\\/\\/wordpress.com\\/\\\">Reader<\\/a>\",\"foldBar\":\"Collapse this bar\",\"unfoldBar\":\"Expand this bar\",\"editFollows\":\"Manage Sites I Follow\",\"editSubs\":\"Manage Subscriptions\",\"viewReader\":\"View Site in the Reader\",\"subscribe\":\"Sign me up\",\"enterEmail\":\"Enter your email address\",\"followers\":\"\",\"alreadyUser\":\"Already have a WordPress.com account? <a href=\\\"https:\\/\\/chelate.wordpress.com\\/wp-login.php?redirect_to=https%3A%2F%2Fchelate.wordpress.com%2Freport%2F\\\">Log in now.<\\/a>\"}};\n/* ]]> */\n</script>\n<script type='text/javascript' src='https://s1.wp.com/_static/??-eJx9ykEOQDAQQNELYQhRG3GWaie0alTbwfHZsbL7yX9w+lxtlJAS2AgaD6PQX4WNGXzWyrl3PBmK4MyCEXZGxlmSdhh+sFTJbDTK8Najh7WvGtHWddeK0t63KC/k'></script>\n<script type=\"text/javascript\">\n// <![CDATA[\n(function() {\ntry{\n  if ( window.external &&'msIsSiteMode' in window.external) {\n    if (window.external.msIsSiteMode()) {\n      var jl = document.createElement('script');\n      jl.type='text/javascript';\n      jl.async=true;\n      jl.src='/wp-content/plugins/ie-sitemode/custom-jumplist.php';\n      var s = document.getElementsByTagName('script')[0];\n      s.parentNode.insertBefore(jl, s);\n    }\n  }\n}catch(e){}\n})();\n// ]]>\n</script>\t<script type=\"text/javascript\">\n\tvar skimlinks_pub_id = \"725X584219\"\n\tvar skimlinks_sitename = \"chelate.wordpress.com\";\n\t</script>\n\t<script type=\"text/javascript\" src=\"https://s.skimresources.com/js/725X1342.skimlinks.js\"></script>\t\t<iframe src='https://widgets.wp.com/likes/master.html?ver=20160429#ver=20160429' scrolling='no' id='likes-master' name='likes-master' style='display:none;'></iframe>\n\t\t<div id='likes-other-gravatars'><div class=\"likes-text\"><span>%d</span> bloggers like this:</div><ul class=\"wpl-avatars sd-like-gravatars\"></ul></div>\n\t\t<script>\n\t\t\tvar _comscore = _comscore || [];\n\t\t\t_comscore.push({\n\t\t\t\tc1: \"2\",\n\t\t\t\tc2: \"7518284\"\n\t\t\t});\n\t\t\t(function() {\n\t\t\t\tvar s = document.createElement(\"script\"),\n\t\t\t\t\tel = document.getElementsByTagName(\"script\")[0];\n\t\t\t\ts.async = true;\n\t\t\t\ts.src = (document.location.protocol == \"https:\" ? \"https://sb\" : \"http://b\") + \".scorecardresearch.com/beacon.js\";\n\t\t\t\tel.parentNode.insertBefore(s, el);\n\t\t\t})();\n\t\t</script>\n\t\t<noscript>\n\t\t\t<p class=\"robots-nocontent\"><img src=\"https://sb.scorecardresearch.com/p?c1=2&c2=7518284&c3=&c4=&c5=&c6=&c15=&cv=2.0&cj=1\" alt=\"\" style=\"display:none;\" width=\"1\" height=\"1\" /></p>\n\t\t</noscript><script src=\"//stats.wp.com/w.js?55\" type=\"text/javascript\" async defer></script>\n<script type=\"text/javascript\">\n_tkq = window._tkq || [];\n_stq = window._stq || [];\n_tkq.push(['storeContext', {'blog_id':'1243944','blog_tz':'0','user_lang':'en','blog_lang':'en','user_id':'0'}]);\n_stq.push(['view', {'blog':'1243944','v':'wpcom','tz':'0','user_id':'0','post':'10','subd':'chelate'}]);\n_stq.push(['extra', {'crypt':'UE40eW5QN0p8M2Y/RE1LVmwrVi5vQS5fVFtfdHBbPyw1VXIrU3hWLHhzVndTdktBX0ddJnpXRjVaOTd6fj1YMX4ydzR6MmRCYnxkNmdpPTBtMEFwTjQ0NWlURCVDWHdySjh8XVMzP1V+ZlNZQS9uUHRpTSZuODFXZ1Z4aXgxL2dLUUFSUi5CWD1EWSZHMU1UMkFYQS5GR3dMZkkuLlZCN3VZVHpRWU1PNElzektmQ1h3TGJyKy55RUI0JUlafC8weTFhaWprTSY2M3QmWll4S1pQeiYvMnVjdkxGZDk2cmRJRWpqQVtiayY4XW00P3Q='}]);\n_stq.push([ 'clickTrackerInit', '1243944', '10' ]);\n\t</script>\n<noscript><img src=\"https://pixel.wp.com/b.gif?v=noscript\" style=\"height:0px;width:0px;overflow:hidden\" alt=\"\" /></noscript>\n<script>\nif ( 'object' === typeof wpcom_mobile_user_agent_info ) {\n\n\twpcom_mobile_user_agent_info.init();\n\tvar mobileStatsQueryString = \"\";\n\t\n\tif( false !== wpcom_mobile_user_agent_info.matchedPlatformName )\n\t\tmobileStatsQueryString += \"&x_\" + 'mobile_platforms' + '=' + wpcom_mobile_user_agent_info.matchedPlatformName;\n\t\n\tif( false !== wpcom_mobile_user_agent_info.matchedUserAgentName )\n\t\tmobileStatsQueryString += \"&x_\" + 'mobile_devices' + '=' + wpcom_mobile_user_agent_info.matchedUserAgentName;\n\t\n\tif( wpcom_mobile_user_agent_info.isIPad() )\n\t\tmobileStatsQueryString += \"&x_\" + 'ipad_views' + '=' + 'views';\n\n\tif( \"\" != mobileStatsQueryString ) {\n\t\tnew Image().src = document.location.protocol + '//pixel.wp.com/g.gif?v=wpcom-no-pv' + mobileStatsQueryString + '&baba=' + Math.random();\n\t}\n\t\n}\n</script>\n</body>\n</html>", "expected-search-type": "f"}